Is Shalby (SHALBY) overvalued or fairly valued?

MarketChacha shows Shalby's valuation in context — a forward P/E of about 16.5, a price-to-book of about 1.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Shalby's revenue?

Shalby reported revenue of ₹899 Cr for FY2026, with net profit of ₹113 Cr, per official filings.

What is the share price of Shalby (SHALBY)?

Shalby last traded at ₹155.21 (+1.6% on the day), as of 8/19/2026 — a delayed quote shown for education, not investment advice.

Shalby

SHALBY · NSE · Healthcare · India

Snapshot

TickerSHALBY

ExchangeNSE

SectorHealthcare

IndustryMedical Care Facilities

CountryIndia

CEOMr. Daniel Hayes

HeadquartersAhmedabad, India

Websitewww.shalby.org

Filings tracked5

About Shalby

Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, orthopedic and trauma, arthroscopy, and arthroplasty; cardiothoracic and vascular surgery, coronary angiography, angioplasty and stenting, and cardiology services; root canal treatment, dental implants, crowns bridges, dentures, orthodontic treatment, dental cosmetic, teeth whitening, pediatric dentistry, dental veneers, gum treatment, and laser dentistry; dermatology; emergency and general medicine; cochlear implants and balloon sinuplasty; gastroenterology, obesity surgery, and endoscopy and laparoscopy; intensive and critical care; nephrology, urology, kidney transplant, dialysis, and interventional nephrology; and general surgery comprising varicose, hernia, and piles surgery. The company also provides liver transplant; maxillofacial surgery; neurology, ideal stroke treatment, epilepsy, endovascular/interventional neurosurgery, and trans cranial doppler; obstetrics and gynaecology; surgical oncology, medical oncology, radiation oncology, bone marrow transplant, onco-psychology, onco-dietetics, onco-physiotherapy, and home care; ophthalmology; paediatrics; pathology and microbiology; psychiatry; pulmonology and chest; and interventional and diagnostic radiology. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is based in Ahmedabad, India.

Who owns it

Promoters76.6%
Institutions0.1%
Public & other23.4%

6 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend9.8% → 12.6%

Margin has expanded by about 2.7 points — the business is getting more profitable.

Growth qualityrev 20% · PAT 28%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (BSE (official results filing)). Education, not a rating or recommendation.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Annual

Quarterly · last 7

Revenue (FY2026)

₹899 Cr

Net margin

12.6%

Revenue CAGR (4y)

+20.2%

Profit CAGR (4y)

+27.7%

EPS (FY2026)

10.50

Net profit (FY2026)

₹113 Cr

Ask MarketChacha about SHALBY

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹899 Cr	₹113 Cr	10.50	12.6%
FY2025	₹1,087 Cr	₹6 Cr	—	0.6%
FY2024	₹953 Cr	₹83 Cr	—	8.8%
FY2023	₹827 Cr	₹68 Cr	—	8.2%
FY2021	₹431 Cr	₹42 Cr	—	9.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
Q1 FY27	₹254 Cr	₹25 Cr	2.33	9.9%
Q4 FY26	₹225 Cr	₹54 Cr	4.99	23.9%
Q3 FY26	₹215 Cr	₹14 Cr	1.28	6.4%
Q4 FY23	₹208 Cr	—	—	—
Q3 FY23	₹202 Cr	₹15 Cr	—	7.5%
Q2 FY23	₹202 Cr	₹18 Cr	—	9.1%
Q1 FY23	—	₹20 Cr	—	—

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

Filings & announcements

2026

Business Responsibility and Sustainability Reporting (BRSR)
BRSR Report for FY 2025-26
BSE8/17/2026
Allotment of ESOP / ESPS
Exercise of ESOP
BSE8/10/2026
Availing Of Working Capital Facilities
Availing working capital facilities from Kotak Mahindra Bank Limited
BSE7/30/2026
Update on board meeting
The Board Meeting to be held on 05/08/2026 has been revised to 12/08/2026 The Board Meeting to be held on 05/08/2026 to consider unaudited financial results for quarter ended June 30, 2026 ....
BSE7/27/2026material
Credit Rating
Credit Rating
BSE7/27/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.